Brought to you by 
BioCryst nets $29.9mm in private placement
26 Oct 2012
Executive Summary
BioCryst Pharmaceuticals (enzyme blockers for cancer and cardiovascular, autoimmune, and infectious diseases) netted $29.9mm through the private placement of 2.2mm common shares priced at $13.46 each (a 9% discount to market). Institutional investors included Kleiner Perkins Caufield & Byers and Texas Pacific Group Ventures.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioCryst nets $29.9mm in private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice